Why the study?
Does torasemide improve peak VO2, NT-proBNP levels, or quality of life in patients with compensated left ventricular systolic dysfunction on optimal medical therapy?
Does torasemide improve peak VO2, NT-proBNP levels, or quality of life in patients with compensated left ventricular systolic dysfunction on optimal medical therapy?
Routine use of torasemide in patients with compensated left ventricular systolic dysfunction does not improve exercise capacity or natriuretic peptides, and may cause potentially harmful neuroendocrine activation and blood pressure reduction.
No takes yet. Share an insight, caveat, or question.
Torasemide lacks benefit on exercise capacity or NT-proBNP in compensated LV systolic dysfunction; challenges routine use and highlights potential harm.
Gupta et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: